CSL Limited (CSLLY)
USD 87.11
(0.13%)
USD 87.11
(0.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 3.7 Billion USD | -57.73% |
| 2023 | 4.88 Billion USD | 15.2% |
| 2022 | 4.23 Billion USD | 1.56% |
| 2021 | 4.17 Billion AUD | 6.05% |
| 2020 | 3.93 Billion AUD | 10.36% |
| 2019 | 3.56 Billion AUD | 103.09% |
| 2018 | 1.75 Billion AUD | 35.04% |
| 2017 | 1.3 Billion AUD | 28.58% |
| 2016 | 1.01 Billion AUD | -28.92% |
| 2015 | 1.42 Billion AUD | 11.78% |
| 2014 | 1.27 Billion AUD | 12.21% |
| 2013 | 1.13 Billion AUD | 24.0% |
| 2012 | 914.81 Million AUD | -6.2% |
| 2011 | 975.24 Million AUD | 7.26% |
| 2010 | 909.25 Million AUD | 32.72% |
| 2009 | 685.1 Million AUD | 16.76% |
| 2008 | 586.78 Million AUD | 26.79% |
| 2007 | 462.78 Million AUD | 1490.44% |
| 2006 | 29.09 Million AUD | -84.09% |
| 2005 | 182.85 Million AUD | 894.66% |
| 2004 | 18.38 Million AUD | -52.53% |
| 2003 | 38.72 Million AUD | -41.15% |
| 2002 | 65.8 Million AUD | 262.02% |
| 2001 | -40.61 Million AUD | -103.86% |
| 2000 | -19.92 Million AUD | -142.04% |
| 1999 | 47.39 Million AUD | 16.42% |
| 1998 | 40.71 Million AUD | -87.2% |
| 1997 | 318.09 Million AUD | 1476.26% |
| 1996 | -23.11 Million AUD | -20.96% |
| 1995 | -19.1 Million AUD | -153.71% |
| 1994 | -7.53 Million AUD | -5.21% |
| 1993 | -7.15 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | 1.12 Billion USD | 0.0% |
| 2024 FY | 3.79 Billion USD | -22.3% |
| 2024 Q1 | 2.03 Billion USD | 145.86% |
| 2024 Q2 | 2.57 Billion USD | 0.0% |
| 2023 Q1 | 1.66 Billion USD | 145.14% |
| 2023 FY | 4.88 Billion USD | 15.2% |
| 2023 Q4 | 826.62 Million USD | 6.83% |
| 2023 Q3 | 773.77 Million USD | -63.2% |
| 2023 Q2 | 2.1 Billion USD | 26.05% |
| 2022 Q4 | 680.53 Million USD | 42.99% |
| 2022 Q2 | 2.18 Billion USD | 42.53% |
| 2022 FY | 4.23 Billion USD | 1.56% |
| 2022 Q3 | 475.92 Million USD | -78.21% |
| 2022 Q1 | 1.53 Billion USD | 113.37% |
| 2021 Q4 | 718.16 Million USD | 41.31% |
| 2021 Q3 | 508.23 Million USD | -78.3% |
| 2021 Q1 | 1.64 Billion USD | 50.9% |
| 2021 Q2 | 2.34 Billion USD | 42.26% |
| 2021 FY | 4.17 Billion AUD | 6.05% |
| 2020 Q4 | 1.09 Billion USD | 23.76% |
| 2020 FY | 3.93 Billion AUD | 10.36% |
| 2020 Q2 | 1.59 Billion USD | 32.14% |
| 2020 Q1 | 1.2 Billion USD | 27.8% |
| 2020 Q3 | 881.75 Million USD | -44.81% |
| 2019 Q3 | 669.69 Million USD | -39.25% |
| 2019 FY | 3.56 Billion AUD | 103.09% |
| 2019 Q1 | 1.07 Billion USD | 75.87% |
| 2019 Q4 | 945.96 Million AUD | 41.25% |
| 2019 Q2 | 1.1 Billion USD | 2.61% |
| 2018 Q2 | 945.74 Million USD | 0.5% |
| 2018 Q3 | 588.56 Million USD | -37.77% |
| 2018 Q4 | 610.89 Million AUD | 3.8% |
| 2018 FY | 1.75 Billion AUD | 35.04% |
| 2018 Q1 | 941.02 Million USD | 114.55% |
| 2017 Q2 | 758.51 Million USD | 6.07% |
| 2017 Q1 | 715.08 Million USD | 53.99% |
| 2017 FY | 1.3 Billion AUD | 28.58% |
| 2017 Q4 | 438.6 Million AUD | -0.6% |
| 2017 Q3 | 441.23 Million USD | -41.83% |
| 2016 Q3 | 450.13 Million USD | -12.07% |
| 2016 Q4 | 464.38 Million AUD | 3.17% |
| 2016 FY | 1.01 Billion AUD | -28.92% |
| 2016 Q2 | 511.91 Million USD | -3.47% |
| 2016 Q1 | 530.28 Million USD | -7.21% |
| 2015 Q3 | 576.7 Million USD | 7.46% |
| 2015 Q2 | 536.66 Million USD | 6.9% |
| 2015 Q1 | 502.01 Million USD | 15.59% |
| 2015 FY | 1.42 Billion AUD | 11.78% |
| 2015 Q4 | 571.51 Million AUD | -0.9% |
| 2014 Q3 | 441.77 Million USD | -3.4% |
| 2014 FY | 1.27 Billion AUD | 12.21% |
| 2014 Q1 | 437.56 Million USD | 14.96% |
| 2014 Q4 | 434.31 Million AUD | -1.69% |
| 2014 Q2 | 457.32 Million USD | 4.51% |
| 2013 FY | 1.13 Billion AUD | 24.0% |
| 2013 Q2 | 376.92 Million USD | -0.06% |
| 2013 Q4 | 380.62 Million AUD | 13.7% |
| 2013 Q1 | 377.16 Million USD | 0.0% |
| 2013 Q3 | 334.77 Million USD | -11.18% |
| 2012 FY | 914.81 Million AUD | -6.2% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | 975.24 Million AUD | 7.26% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 909.25 Million AUD | 32.72% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 685.1 Million AUD | 16.76% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 586.78 Million AUD | 26.79% |
| 2007 FY | 462.78 Million AUD | 1490.44% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 29.09 Million AUD | -84.09% |
| 2005 FY | 182.85 Million AUD | 894.66% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | 18.38 Million AUD | -52.53% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | 38.72 Million AUD | -41.15% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | 65.8 Million AUD | 262.02% |
| 2001 FY | -40.61 Million AUD | -103.86% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | -19.92 Million AUD | -142.04% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | 47.39 Million AUD | 16.42% |
| 1998 FY | 40.71 Million AUD | -87.2% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | 318.09 Million AUD | 1476.26% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | -23.11 Million AUD | -20.96% |
| 1995 FY | -19.1 Million AUD | -153.71% |
| 1994 FY | -7.53 Million AUD | -5.21% |
| 1993 FY | -7.15 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 2627364.792% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 539003.85% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 2158580.514% |
| CytoDyn Inc. | -18.05 Million USD | 20600.609% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 6375.64% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | 512167889.599% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 203918.71% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 73487.104% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 12359875.641% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 2039938.003% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 38242.924% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 6769.309% |
| SQZ Biotechnologies Company | -75.82 Million USD | 4982.295% |
| Resverlogix Corp. | -12.74 Million USD | 29137.572% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 950378.512% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -37898.62% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 150874.829% |
| Mesoblast Limited | -84.14 Million USD | 4499.444% |
| GB Sciences, Inc. | -1.42 Million USD | 260710.809% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 539003.85% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 20842.982% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 108823.137% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 55785.795% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 116945.955% |
| ContraFect Corporation | -56.88 Million USD | 6607.409% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 134677.124% |
| BioStem Technologies, Inc. | -7.77 Million USD | 47689.854% |
| LadRx Corporation | -3.82 Million USD | 96919.093% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 23427.419% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 330931.099% |
| Biomind Labs Inc. | -1 Million USD | 366778.784% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 397574.715% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -4422.803% |
| Nascent Biotech, Inc. | -2.22 Million USD | 166117.977% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 5256.994% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -75223.344% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -104476.271% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 241107.937% |
| Marizyme, Inc. | -34.08 Million USD | 10960.6% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 44435.329% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 655642.629% |
| Zenith Capital Corp. | -8.94 Million USD | 41495.505% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 129971.633% |
| Halberd Corporation | -75.05 Thousand USD | 4932811.526% |
| Genus plc | 6.4 Million USD | -57743.75% |
| Pharming Group N.V. | -4.87 Million USD | 75967.745% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 186459.886% |
| IMV Inc. | -38.67 Million USD | 9672.938% |
| Affymax, Inc. | -15.04 Million USD | 24704.546% |
| SYBLEU INC | -149.18 Thousand USD | 2481665.894% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 354697.701% |
| Enzolytics Inc. | -2.14 Million USD | 172382.204% |
| argenx SE | -425.04 Million USD | 970.958% |
| AVAX Technologies, Inc. | 6.69 Million USD | -55212.511% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 264153.05% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 277313.873% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 98914.361% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 14708085.697% |
| Cell Source, Inc. | -4.32 Million USD | 85688.529% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 766461.254% |
| Q BioMed Inc. | -3.44 Million USD | 107540.876% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 87443.992% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 294845.223% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 140993.207% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 81378.215% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 6834.294% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 127700.172% |
| Rebus Holdings, Inc. | -664 Thousand USD | 557630.12% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 376299.249% |
| Skye Bioscience, Inc. | -13.67 Million USD | 27177.634% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 198665.735% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 184760.784% |
| ONE Bio Corp. | 13.68 Million USD | -26958.34% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 191654.426% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 329194.164% |
| Agentix Corp. | -1.37 Million USD | 269973.068% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 126904.967% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 234499.486% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 21250315.257% |
| Kadimastem Ltd | -3.04 Million USD | 121866.302% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 1414556.34% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 891119.763% |
| NovAccess Global Inc. | -2.46 Million USD | 150175.403% |
| Itoco Inc. | -919.14 Thousand USD | 402867.805% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 1682230.881% |
| Qrons Inc. | -643.67 Thousand USD | 575233.18% |
| Mobile Lads Corp. | -554.55 Thousand USD | 667668.299% |
| Genscript Biotech Corporation | -415.79 Million USD | 990.351% |
| International Stem Cell Corporation | -663 Thousand USD | 558471.041% |
| Bioxytran, Inc. | -3.82 Million USD | 97007.266% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 7032774.772% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 18200689.971% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 10307.908% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 228900.989% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 503201.918% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 119097.107% |
| Neutra Corp. | -229.48 Thousand USD | 1613270.302% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 21207.247% |
| PureTech Health plc | -146.19 Million USD | 2632.165% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 17325.719% |
| IXICO plc | -1.43 Million USD | 257720.042% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 39105.374% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 3139.259% |
| CSL Limited | 3.81 Billion USD | 2.886% |
| Cellectis S.A. | -108.85 Million USD | 3500.781% |